Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19945733 | 1.00 | PPM1D (0.30) | PPM1D | |
| SCHEMBL3577011 | 1.00 | PPM1D (0.30) | PPM1D | |
| SCHEMBL17858689 | 0.91 | PPM1D (0.32) | PPM1D | |
| SCHEMBL7391295 | 0.84 | PPM1D (0.30) | PPM1D | |
| SCHEMBL16516673 | 0.83 | PPM1D (0.33) | PPM1D | |
| SCHEMBL29599566 | 0.83 | PPM1D (0.33) | PPM1D | |
| SCHEMBL23851579 | 0.82 | PPM1D (0.31) | PPM1D | |
| SCHEMBL1441148 | 0.82 | PPM1D (0.31) | PPM1D | |
| SCHEMBL14737218 | 0.82 | PPM1D (0.31) | PPM1D | |
| SCHEMBL21104118 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| WO-2025201444-A1 | NOVEL GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| CN-113929618-B | Oxo-pyridine amide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-113912586-B | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115003670-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-113929618-A | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113912586-A | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-112898309-A | Tricyclic compounds as immunomodulators | 正大天晴药业集团股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-8106232-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| WO-2011028596-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-03-10 | — | — | WO | disclosed |
| EP-2231585-A2 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| WO-2009076408-A2 | 3 -CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-4954489-A | ACYLATION | BEECHAM GROUP P.L.C. (GB) | 1990-09-04 | — | — | US | disclosed |
| EP-0337643-A2 | 6-Substituted acrylamido penicillanic acid derivatives, preparation and use | BEECHAM GROUP PLC (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | QDPR, TPMT, PTGIS | PPM1D 1542/4885 |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | PPM1D 3027/4885 |
| US-20110152237-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | PPM1D 3152/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | PPM1D 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.